<p>Abbott Laboratories has received CE Mark approval in Europe for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, for the treatment of patients with atrial fibrillation (AFib). The TactiFlex Duo is designed to deliver both radiofrequency energy and pulsed field ablation (PFA) energy, providing a dual-energy option for treating complex arrhythmias. This approval follows previous regulatory milestones in Abbott’s electrophysiology portfolio, including FDA and CE Mark approvals for the Volt PFA System in 2025. The first commercial procedures using TactiFlex Duo in the European Union have been completed. The device is also under evaluation in the United States as part of the FLEXPULSE IDE trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG66231) on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Abbott Receives CE Mark for TactiFlex Duo Ablation Catheter in Europe